Modality
Vaccine
MOA
STINGag
Target
Nectin-4
Pathway
Wnt
PsAETGIST
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
~Dec 2023
→ ~Mar 2025
Phase 3
Jun 2025
→ Jun 2031
Phase 3Current
NCT08544270
2,690 pts·ET
2025-06→2031-06·Terminated
2,690 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-085.2y awayPh3 Readout· ET
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Termina…
Catalysts
Ph3 Readout
2031-06-08 · 5.2y away
ET
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08544270 | Phase 3 | ET | Terminated | 2690 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Tezelucimab | Ascendis Pharma | Preclinical | SHP2 |